Form D · Pharmaceuticals
Engage Therapeutics, Inc.
Summit, NJ · CIK 0001719075
Offering snapshot reported Oct 29, 2019 · SEC filing
- Reported sold
- $7M Offering amount: $12M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 18, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 29, 2019 | Initial | $6,999,999 | No comparison | 18 | SEC filing |
| Oct 10, 2017 | Initial | $23,600,000 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-352070
Source: Form D, filed Oct 29, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gerry Brunk | Director |
| Stephen Collins | Director |
| Orrin Devinsky | Director |
| Jouko Isojarvi | Executive |
| Warren Lammert | Director |
| Heath Lukatch | Director |
| Gregory Mayes | Director, Executive, Promoter |
| Mark Theeuwes | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
31 Lenox Road
Summit, NJ, 07901
Summit, NJ, 07901